BioCentury | Sep 9, 2020
Product Development

Intra-Cellular eyes broad label for bipolar depression after Phase III hit

...the dual serotonin (5-HT2A) receptor agonist and dopamine receptor...
BioCentury | Dec 23, 2019
Company News

Caplyta’s unanticipated schizophrenia approval lifts Intra-Cellular shares

...to the company’s market cap. The agency approved the dual serotonin (5-HT2A) receptor antagonist and dopamine receptor...
BioCentury | Nov 22, 2019

Dopamine receptor agonism for pulmonary fibrosis, liver fibrosis

...DISEASE CATEGORY: Pulmonary; hepatic INDICATION: Pulmonary fibrosis; liver fibrosis Agonism of the dopamine receptor DRD1 could treat...
BioCentury | Oct 28, 2019

Prolactin inhibition could treat MS

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Inhibition of PRL or ZBTB20, a transcription factor that promotes PRL expression, could treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, CSF levels...
BioCentury | Aug 22, 2019
Distillery Therapeutics

Enhancing dopamine receptor and ghrelin receptor activity to prevent β amyloid damage

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Jointly agonizing DRD1 and the 1α isoform of GHSR could prevent β amyloid's damage in the hippocampus in AD. Postmortem hippocampal brain tissues from AD patients and an...
BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...to treat schizophrenia, citing “new information regarding the application.” Lumateperone is a 5-HT2A antagonist and dopamine receptor...
BioCentury | Jul 8, 2019
Clinical News

Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results

...from five other countries. Lumateperone is a dual serotonin receptor 2A (5-HT2A; HT2RA) antagonist and dopamine receptor...
BioCentury | May 31, 2019
Translation in Brief

New target for Oncoceutics' GPCR-targeting compounds

...Oncoceutics’ management team told BioCentury its lead product, ONC201, directly antagonizes DRD2 and a related dopamine receptor...
...of medicine at University of Texas MD Anderson Cancer Center, leukemic cells don't express detectable dopamine receptor...
...loss of ONC212-mediated survival in mice. Graves believes CLPP activation better explains ONC201's efficacy than dopamine receptor...
BioCentury | Feb 1, 2019
Clinical News

FDA wants more info on Sunovion Parkinson’s therapy

...are required. APL-130277 is a sublingual thin film strip formulation of apomorphine, a small molecule dopamine receptor...
...Japan Product: Apomorphine sublingual film (APL-130277) Business: Neurology Hongjiang Li apomorphine (APL-130277) Aquestive Therapeutics Inc. Sumitomo Dainippon Pharma Co. Ltd. Dopamine receptor...
BioCentury | Jan 31, 2019
Company News

FDA wants more info on Sunovion Parkinson’s therapy

...are required. APL-130277 is a sublingual thin film strip formulation of apomorphine, a small molecule dopamine receptor...
...Thursday. Aquestive was off $1.02 (14%) to $6.13. Hongjiang Li apomorphine (APL-130277) Aquestive Therapeutics Inc. Sumitomo Dainippon Pharma Co. Ltd. Dopamine receptor...
Items per page:
1 - 10 of 361